Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Anna Pavlick, MD
Advertisement
Articles by Anna Pavlick, MD
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Advertisement
Latest Updated Articles
Dr. Anna Pavlick on Options for First-Line Therapy in Late-Stage MelanomaPublished: June 13th 2019 | Updated:
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in RemissionPublished: June 20th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
3
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
4
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm
5
